Zydus receives FDA priority review for Saroglitazar for PBC
The US FDA granted Priority Review for the NDA of Saroglitazar to treat Primary Biliary Cholangitis.
See the latest news and media coverage for Zydus. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company
zyduslife.comLast updated
In short: Zydus advanced its specialty pipeline with FDA priority review for Saroglitazar and reported strong Q4 FY26 earnings alongside a $166M acquisition.
The US FDA granted Priority Review for the NDA of Saroglitazar to treat Primary Biliary Cholangitis.
Pharma business grew across regions, with EBITDA margin improving to 33.7%.
The all-cash tender offer agreement was announced between the two companies.
TwinRab advances to represent India at International Prix Galien 2028 in USA.
Zydus Lifesciences Limited has successfully concluded its buyback of 87,30,158 equity shares at ₹1,260 per share, utilizing ₹1,099.99 crore. The offer was subscribed 93.61 times...
Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a...
The U.S. Food and Drug Administration (U.S. FDA) has issued a warning letter to Zydus Lifesciences relating to the company's formulation manufacturing facility in Baddi...
The Zydus Lifesciences stock has gained 20 per cent over the past month and has been the best-performing pharmaceutical stock during this period as well...
Track Zydus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Zydus and other trending companies.